Realm Therapeutics PLC Stock

PURI

GB00B3XBCR18

Biotechnology & Medical Research

Delayed London S.E.			5-day change	1st Jan Change
- ^GBX	-.--%		+9.52%	+64.29%

Press Releases: Realm Therapeutics PLC

19/07/19	Realm Therapeutics : Update on Company’s Nasdaq Listing	PU
09/07/19	Realm Therapeutics : Update on Court Hearing	PU
06/07/19	Realm Therapeutics : Announces Final Net Cash Amount and Exchange Ratio	PU
03/07/19	Realm Therapeutics : announces updated expected timetable of principal events in connection with the Acquisition by Essa	PU
16/02/19	Realm Therapeutics : "Realm Therapeutics", "Realm" or the "Company"), Update on Strategic Review, Proposed Assets Disposal, Proposed Adoption of Investing Policy, Proposed AIM Delisting and Notice of General Meeting	PU

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REALM THERAPEUTICS PLC	-.--%	+9.52%	-	-	11.66M
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	64.38B
ARGENX SE	+0.99%	+3.86%	+15.66%	+85.73%	56.16B
LONZA GROUP AG	+0.25%	+2.15%	+15.58%	+107.19%	54.16B
IQVIA HOLDINGS INC.	-2.66%	-4.14%	+23.71%	+51.16%	45.33B
BEONE MEDICINES AG	+0.25%	-1.21%	+21.04%	+99.92%	42.25B
REVOLUTION MEDICINES, INC.	-0.76%	+1.13%	+221.23%	+930.57%	40.78B
GENMAB A/S	+2.93%	+47.43%	+111.91%	+95.78%	33.8B
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	23.57B
Average	+0.04%	+4.72%	+53.11%	+163.39%	43.63B
Weighted average by Cap.	+0.00%	+3.64%	+49.96%	+161.88%

See all sector performances

Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.

Employees

Sector

Biotechnology & Medical Research

More about the company